Objective: Dietary carotenoids (lutein, lycopene and b-carotene) may be important in preventing or ameliorating prematurity complications. Little is known about carotenoid status or effects of supplementation.
Introduction
More than 600 different carotenoids, bioactive substances made by plants and bacteria, are found in nature. Approximately 30 have been identified in human serum and breast milk, lutein, lycopene and b-carotene being among the most abundant. 1 Carotenoids possess antioxidant, anti-inflammatory and light-absorbing characteristics. Accumulating evidence has implicated carotenoid consumption with a decreased risk of age-related diseases including adult-onset macular degeneration, 2 atherosclerosis 3 and certain tumors. 4 It is relevant that perinatal inflammation, often caused or exacerbated by oxidative stress, features in the pathogenesis of common diseases of prematurity. [5] [6] [7] Several investigators have suggested dietary carotenoids might enhance retinal function in infants [8] [9] [10] [11] and protect against inflammation and oxidative damage. [12] [13] [14] [15] [16] However, research into this important subject in neonatal nutrition is limited. Plasma carotenoid concentrations significantly decline in formula-fed infants immediately following birth compared with their breast-fed counterparts. [17] [18] [19] Recently, several small studies have approached issues of carotenoid bioavailability 20, 21 and putative anti-oxidant effects 16 in preterm newborns. We report the first comprehensive, randomized controlled trial designed to assess feasibility and potential benefits of supplementing preterm infant formulas with the carotenoids lutein, lycopene and b-carotene.
Methods
This study used a double-blind, randomized, controlled, parallel multicenter design (Supplementary Information 1). Preterm infants (n ¼ 203) from one to 21 days of age were enrolled and, within 72 h of attaining X30 ml kg À1 per day enteral feeding, were randomized to receive carotenoid supplemented formula (SF) or control formula (CF) until 40 weeks post-menstrual age (PMA). At that time, subjects were switched to the corresponding postdischarge preterm formula (SF, CF) for use until trial end at 50 weeks PMA. A human milk (HM) reference group consisted of infants for whom X80% of their intake to 40 weeks PMA was HM. HM-fed infants also were randomized to one of the two study formulas if HM became insufficient at any time during the study.
Study population
Study subjects, singleton or twin preterm infants born <33 completed weeks of gestation and weighing 500 to 1800 g, were enrolled after obtaining consent from the parent/legally authorized representative. Exclusion criteria included participation in a concurrent clinical trial or the presence of serious congenital abnormalities, intraventricular hemorrhage grade III or IV, asphyxia, necrotizing enterocolitis (NEC), bacteremia or maternal incapacity.
A sample size of 50 in each group was determined to be appropriate for B80% power to detect an effect size of 2/3 (difference between group means of B2/3 s.d.) with a 0.017 (0.05/3) two-sided significance level, preserving an experimentwide alpha of 0.05 over the three primary hypotheses for plasma lutein, lycopene and b-carotene concentrations. Assuming a 25% attrition rate and three study groups (two formula-fed groups and one HM-fed group), 204 subjects (68 per group) were targeted for enrollment. The software nQuery Advisor 5.0 (Statistical Solutions, Saugus, MA, USA) was used for estimation of sample size.
Diets
All study diets were iron-fortified, milk-based ready to feed liquid formulas that included docosahexanoic acid and arachidonic acid. CF contained no added carotenoids. SF contained a mixture of lutein/zeaxanthin, lycopene and b-carotene. The b-carotene (Lucarotin) and lycopene (Lycovit) were supplied by BASF (Florham Park, NJ, USA). Lutein (FloraGlo Lutein) was supplied by Kemin Health, LC (Des Moines, IA, USA). The in-hospital study formula was Similac Special Care 24 kcal/oz and post-discharge study formula was Similac NeoSure 22 kcal/oz supplied by Abbott Nutrition (Columbus, OH, USA). Study macronutrient and carotenoid concentrations appear in Table 1 .
Carotenoid analysis
Plasma samples were collected on study day (SD) 1, hospital discharge, 40 weeks and 50 weeks PMA. Plasma concentrations of carotenoids (lutein, zeaxanthin, trans-lycopene, cis-lycopene, trans-b-carotene, cis-b-carotene) were measured by Craft Technologies (Wilson, NC, USA) using reverse phase high performance liquid chromatography with ultraviolet detection at 450 nm as described previously. 22 The collection and storage procedures did not degrade analyte quantification (data not shown). We combined cis-and trans-isomers and report total lycopene and b-carotene. The lutein all-trans isomer is reported as total lutein.
Growth and feeding tolerance
Subjects' daily weights and weekly length and head circumference measurements as well as daily enteral intake and formula tolerance were recorded in the hospital. After hospital discharge, parents completed 3-day infant dietary intake and stool diaries before the 40, 44 and 50 week PMA post-discharge visits.
C-reactive protein Plasma C-reactive protein (CRP) was analyzed at SD 1, hospital discharge, 40 and 50 weeks PMA using a sandwich enzyme-linked immunosorbent assay as previously described. 23 
Electroretinography
Full field electroretinogram (ERG) testing was performed at selected research sites using Espion systems (Diagnosys, Lowell, MA, USA) according to methods described by Fulton et al.
24-26
The ERG is a record of the voltage change that occurs across the retina in response to a brief flash of light. 27 Responses to stimuli were digitized and stored for later analyses.
Adverse events and morbidity data All adverse events (AEs) and serious adverse events (SAEs) were reviewed by neonatologist study investigators who were masked to each subject's study randomization. Detailed information was collected for specific conditions related to prematurity, including NEC (Bell's stage II or greater), 28 sepsis (confirmed by culture), intraventricular hemorrhage, bronchopulmonary dysplasia and retinopathy of prematurity (ROP). Investigators documented the occurrence and clinical outcome of each event.
Statistical analysis
The primary analyses included all available data from all randomized subjects who received any assigned study formula (intent-to-treat, ITT). The ITT statistical approach assumes study procedures and visits continue according to protocol even if those subjects do not reach study completion or product administration is permanently discontinued. b-carotene present in the control formula is inherent to other ingredients. Preterm human milk was not analyzed for carotenoid concentrations in conjunction with the study formulas.
Secondary analyses were performed using the data from those infants who strictly adhered to the feeding protocol. In other words, these subjects were 'evaluable'. Outcome data were classified as evaluable until an exclusion event occurred; exclusion events included correct randomization but incorrect dispensing of assigned formula, unsuccessful blood draws (that is, absent data points), volume of formula intake <60% of total volume during the hospital phase, and days of formula intake <60% of SDs after hospital discharge. A subject was removed from the evaluable analysis if she/he received <1 week of study formula in-hospital or had nothing by mouth for at least 10 days. These criteria guaranteed that infants in the evaluable group received at least 90% of their intake as assigned formula (SF or CF). All variables were analyzed using two-sided 0.05 level tests for main effects and 0.10 level tests for interactions. All analyses were done using SAS version 8.2 or higher (SAS Institute, Cary, NC, USA).
As there were three primary variables (plasma concentrations of lutein, lycopene and b-carotene), we adopted a conservative approach in which significance levels were adjusted for multiple endpoints (0.05/3 ¼ 0.0167), preserving an experiment-wide error at the 5% level. No adjustments were made for multiple secondary, supportive or exploratory variables. Pre-specified covariates were used to stratify the randomization including birth weight, gender, HM intake and study site. Categorical variables were analyzed using Cochran-Mantel-Haenszel tests controlling separately for site and amount of HM feeding. Continuous variables obtained at single or multiple time points were analyzed, respectively, using single measure or repeated measures analysis of variance and/or analysis of covariance that accommodate for missing observations.
Results
A total of 203 preterm infants were enrolled and randomized. At trial completion, 183 subjects were in the ITT group, 91 in the control and 92 in the supplemented group. Fifty one of the randomized subjects received >80% of their dietary intakes as HM by 40 weeks PMA. Consequently, they constituted a preterm HM comparison. At trial end, 52 and 46 subjects in the control and supplemented groups, respectively, were evaluable by the criteria specified in Methods above. Disposition of trial subjects is specified in Supplementary Information 1. At randomization, the number of extremely low birth weight (ELBW, <1000 g BW) neonates was similar between the groups. However, more than twice as many SF (n ¼ 17) as CF (n ¼ 8) ELBWs completed the study.
Baseline demographic characteristics for the study groups at birth and randomization are listed in Table 2 . The sole difference was subjects randomized to the SF group had lower mean BW than the CF subjects (P<0.05). Similarly, in males, mean length was less in SF subjects (P<0.05). These differences are consistent with the disproportionately higher number of SF ELBW infants. Among subjects who successfully completed the trial, growth measures did not significantly differ between the groups ( Supplementary  Information 2) .
Subjects who completed the study (that is, evaluable) received B90% of their enteral intake from the assigned study feeding (SF or CF). Also, formula intakes were similar between the groups throughout the trial. Table 3 indicates that SF and CF mean plasma lycopene and b-carotene concentrations were equal at randomization, but plasma lutein was statistically higher in the SF neonates (P<0.01). Throughout the feeding trial, supplementation raised plasma carotenoid levels (P<0.0001). Figure 1 indicates the effect of carotenoid supplementation on plasma carotenoid levels. In the evaluable group, mean plasma lutein levels in the SF subjects were 2.41 and 7.68 mcg dl À1 at SD 1 and 50 weeks PMA (10 weeks corrected age), respectively. In comparison, mean plasma lutein levels in term HM-fed infants were 5.88 mcg dl À1 (range 0.49 to 20.09) at B10 to 13 weeks of age. The mean plasma lutein in the SF group peaked at 40 weeks PMA (10.30 mcg dl À1 ). Mean plasma lycopene in the SF group was 1.33 and 10.78 mcg dl À1 at SD 1 and 50 weeks PMA, respectively. In comparison, mean plasma lycopene in term (Figure 1) . These results confirm a recent observation 20 that lutein content in formula needs to be Bfour times greater than in HM lutein content in order to achieve similar plasma lutein levels.
There were no differences between the two study groups in growth. For subjects who adhered to the feeding protocol, weight gain in hospital was 18.2 and 17.4 g kg À1 per day for the CF and the SF, respectively. These growth rates are consistent with recent recommendations for a weight gain of 18 g kg À1 per day in preterm infants. 29 (Supplementary Information 2 contains trial growth data.)
There were no clinically meaningful differences in measures of feeding tolerance in infants fed SF and CF, for example, no difference in study formula intake, daily gastric residuals, vomiting, or abdominal distention during hospitalization or in feeding tolerance after hospital discharge.
Among subjects completing the study protocol, plasma CRP levels at 40 weeks PMA were significantly lower in the SF than CF Figure 1 Dietary intake and plasma carotenoid concentrations of preterm infants fed control and study formula at 50 weeks post-menstrual age (10 weeks corrected age) and a historical reference group of term infants at B10 to 13 weeks of age (unpublished data, Abbott Nutrition). CF, control formula; HM, human milk (term); SF, supplemented formula.
group (means 0.54 vs 3.25; P<0.001, Figure 2 ). The HM group, which had larger and later gestational age infants, had lower mean CRP levels than the preterm study groups. Nevertheless, the SF mean CRP approximated that of the HM group at post-randomization time points. The incidence of ROP between the two groups was not statistically different in the ITT analysis. In the SF group, 71 of 92 infants were evaluated for ROP whereas, in the CF group, 55 out of 91 infants were evaluated, reflecting the greater number of SF subjects who, by gestational age and BW, met standard ROP screening criteria. The incidence of ROP was 13% (CF group) and 19% (SF group). However, among infants who had mild ROP at point of diagnosis, fewer developed severe ROP (stage 3 to 5) in the SF (8%) than CF (28%) group.
For the ERG outcomes, we report the analysis of all (that is, ITT) subjects in Table 4 (an inadequate number of infants in the evaluable group prevented statistical comparison of ERG outcomes). In post hoc analysis, plasma lutein concentrations at 50 weeks PMA were significantly correlated with the saturated response amplitude in rod photoreceptors (R ROD ) (r ¼ 0.361, P ¼ 0.05). SF infants also showed a significantly greater sensitivity response in rod photoreceptors (S ROD ) than did the CF group (least squares means: 6.1 vs 4.1; P<0.05). This analysis controlled for HM intake. Subjects having ROP were excluded from this analysis as these infants often have altered responses from preterm infants who do not have ROP. 24, 25, 30 There were no significant differences for other scotopic or photopic ERG parameters.
As the SF group included a disproportionate number of ELBW infants, statistical analysis of AEs and SAEs controlled for birth weight. The overall incidence of AEs or incidence of any specific AE did not differ between the formula groups. A majority of the most commonly reported AEs related to the gastrointestinal system (that is, constipation, diarrhea, flatulence, spitting up, vomiting). Similarly, there were no differences in the overall incidence of SAEs or incidence of any specific SAE between groups.
Although the groups did not differ in either confirmed NEC (SF 8%, CF 5%) or sepsis (SF 13%, CF 9%), the greater number of ELBW infants in the SF group would be expected to yield more adverse outcomes. But when we analyzed the subset of study subjects with birth weight >1000 g, cases of confirmed NEC (SF 3%, CF 4%) and sepsis (SF 4%, CF 8%), no differences emerged. HM values were obtained from preterm infants who were 80 vol% fed HM at the corresponding time points in this study. CF, control formula; HM, human milk; SD 1, study day 1; SF, supplemented formula.
Discussion
Preterm infants are particularly disadvantaged with respect to plasma and tissue carotenoid concentrations, as they have been deprived of transfer of lipophilic nutrients during the last weeks of pregnancy. In an observational study of 53 preterm infants, mean total lutein/zeaxanthin and lycopene rapidly declined in the first 10 days of life. 31 Recently, it has been suggested that carotenoid fortification of term infant formula at the high end of the range of HM content might maximize functional effects without posing safety risk. 20, 32 Our findings demonstrate safety and potential health benefits in a large group of preterm and extremely preterm neonates. This is the first randomized, controlled, double-blind, parallel, multicenter study to assess the effect of feeding a carotenoidsupplemented diet to preterm infants. In the ITT and evaluable analyses, plasma lutein, lycopene and b-carotene levels were considerably higher in the supplemented compared with control subjects. Furthermore, this supplementation profile increased plasma concentrations into the range observed in HM-fed term infants.
The incidence of confirmed NEC in the ITT group is consistent with previous reports on preterm infants. 33, 34 The percentage of subjects with confirmed sepsis in both groups (including nosocomial bloodstream infections) was lower than that previously reported in preterm infants. 35 The trial design was not sufficiently powered to determine any study group differences in these specific outcomes.
CRP plasma concentrations were assayed as a marker of inflammation. 36, 37 In these high-risk neonates, carotenoid supplementation was associated with a blunted increase in CRP concentrations from SD 1 to 40 weeks PMA (that is, similar to the HM reference group), whereas CRP levels rose in controls. By 50 weeks PMA, a time when most infants were healthy, the groups' mean CRP levels were similar. The association of lower CRP with higher carotenoid consumption likely reflects carotenoid antioxidant and immunomodulatory properties. A significant inverse correlation previously was shown between serum CRP and b-carotene and retinol concentrations in children with acute infections. 38 Further investigation into carotenoid anti-inflammatory effects in sick, preterm infants is warranted.
It has been suggested, but not experimentally verified, that dietary lutein enhances visual development in infancy. 11, 14, 21 This trial provides the first evidence that lutein may improve neuroretina health in neonates, especially in preterm infants who are at risk for retinopathy and vision loss. We found that plasma lutein concentrations correlate with the saturated response amplitude in rod photoreceptors. In addition, excluding ROP subjects (where S ROD measures are abnormal), lutein-supplemented preterm infants had greater rod photoreceptor sensitivity responses than controls. Consequently, we propose supplementation for preterm neonates may protect photoreceptors and, thereby, affect retinal development. Mechanisms may involve lutein's light absorbing, antioxidant 39 and/or anti-inflammatory 40 activities. These same pathways appear to have a critical role in preventing ROP development and/or progression. The magnitude of the clinical impact of lutein supplementation on macular development and ROP remains unknown.
In conclusion, this study supports the feasibility of adding carotenoids to preterm infant formula. Carotenoid supplementation appears to be safe and effective in producing plasma concentrations similar to those observed in HM-fed term infants. Adding carotenoids to preterm infant formula may have additional benefits related to retinal neurovascular development and suppression of inflammation.
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